|Bid||76.23 x 0|
|Ask||76.38 x 0|
|Day's Range||75.82 - 75.82|
|52 Week Range||48.03 - 76.27|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Two important questions to ask before you buy Express Scripts Holding Company (NASDAQ:ESRX) is, how it makes money and how it spends its cash. What is left after investment, determinesRead More...
Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new gene therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.
Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc, Spark Therapeutics Inc and Bluebird Bio Inc to have its specialty pharmaceutical business exclusively distribute their new hemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.
Express Scripts (ESRX) needs investors to pay close attention to the stock based on moves in the options market lately.
The recommendation is at odds with billionaire investor Carl Icahn’s efforts to drum up investor opposition to the takeover of the pharmacy benefit manager ahead of an Aug. 24 shareholder vote. Institutional Shareholder Services Inc. urged investors to support the deal. “For investors with exposure to both sides of this equation, the value proposition of a combination is straightforward: the potential benefits of the combination outweigh the risks, especially given that these risks are, to some degree, unavoidable,” ISS said in the report.
Activist investor Carl Icahn’s push to derail Cigna Corp.’s proposed $54 billion takeover of pharmacy-benefits firm Express Scripts Holding Co. isn’t convincing one big shareholder. Glenview Capital Management LLC publicly backed the deal on Thursday in a letter to Cigna shareholders, urging other investors to do the same, saying the company is actually paying a cheap price for Express Scripts compared with similar takeovers in the past. “Sensationalist headlines and intentionally misleading assertions from those with conflicting interests and limited analysis should not carry more weight than balanced diligence,” Glenview said in 13-page letter.
The Cigna-Express Scripts deal has drawn investor scepticism over concerns that Amazon.com Inc's (AMZN.O) entry into healthcare will upend the sector at a time when U.S. President Donald Trump has made a push to lower drug prices. "Cigna is dramatically overpaying for a highly challenged Express Scripts that is facing existential risks," Icahn wrote in an open letter about the deal.
The Cigna-Express Scripts deal has drawn investor skepticism over concerns that Amazon.com Inc's (AMZN.O) entry into healthcare will upend the sector at a time when U.S. President Donald Trump has made a push to lower drug prices. "Cigna is dramatically overpaying for a highly challenged Express Scripts that is facing existential risks," Icahn wrote in an open letter about the deal.
Express Scripts Holding (ESRX) and Cigna (CI) are both trading higher on Tuesday, as activist investor Carl Icahn made his unhappiness about their proposed merger public. Express Scripts has reversed earlier losses and is trading higher on Tuesday afternoon, after activist investor Carl Icahn officially c ame out against its merger with Cigna, which is also rising. The announcement isn't much of a surprise, as we've known for some time that Icahn was against the deal and could seek to sway investors against the deal.
Carl Icahn is late to the party on Cigna Inc.’s intended $54 billion purchase of pharmacy-benefit-management giant Express Scripts Holding Co. His Tuesday letter opposing the transaction comes just weeks before an Aug. 24 shareholder vote on whether to approve it. That will make derailing the deal a tough task for the legendary activist, who owns a modest 0.56 percent of Cigna’s shares.
Express Scripts Holding Co. said it will drop 48 drugs next year from its closely watched lineup of covered therapies, including Gilead Sciences Inc.’s HIV treatment Atripla and AbbVie Inc.’s hot-selling Mavyret medicine for hepatitis C. The drug-benefit manager also won’t cover Sanofi’s hemophilia treatment Eloctate next year, it said in a statement. Express Scripts and other pharmacy-benefit managers negotiate rebates from brand-name pharmaceutical companies in exchange for including drugs on their coverage lists.
Activist investor Carl Icahn said shareholders in Cigna Corp. should vote against the $54 billion takeover of pharmacy-benefits firm Express Scripts Holding Co. because the health insurer is “dramatically overpaying” for a company facing existential threats. “Cigna management is offering to pay an all-time high price for a company that, as a result of secular changes, is currently standing on very dangerous ground,” the billionaire wrote in an open letter to shareholders on Tuesday. Icahn disclosed a 0.56 percent stake in Cigna and said he’s betting against Express Scripts.
Billionaire activist Carl Icahn's influence on Cigna Corp.'s takeover bid of Express Scripts Holding Co., was felt, but not heard on Cigna's second-quarter call with analysts. Bloomberg Opinion's Brooke ...
The dismantling of the Affordable Care Act (ACA), also known as Obamacare, and a deregulatory wave across affected states is underpinning profits, while the domestic focus of the health insurance companies is offering safe haven against trade war headwinds. Humana Inc. ( HUM) beat second quarter profit expectations by 18 cents while guiding fiscal year 2018 above consensus. Humana has competed with Dow component UnitedHealth Group Incorporated ( UNH) for industry leadership in recent years, matching rally leg for rally leg.
Billionaire hedge fund manager Carl Icahn has amassed a sizable stake in health insurance industry giant Cigna Corp. ( CI) and plans to vote against its proposed $54 billion acquisition of Express Scripts Holding Co.
Billionaire activist Carl Icahn’s name was on everyone’s minds and no one’s lips Thursday morning when Cigna Corp. held its second-quarter earnings call with Wall Street analysts. Icahn is said to have taken a stake in the health insurer and to oppose its $54 billion takeover of Express Scripts Holding Co. His interest sent Express Scripts shares plunging and Cigna’s stock up on Wednesday as investors bet against the deal’s completion. Icahn hasn’t yet gone public with his stake, which was described by people familiar with the matter.
Express Scripts (ESRX) witnesses year-over-year decline in adjusted network claims in Q2, thanks to the loss of certain public sector clients.
Among the companies with shares expected to trade actively in Thursday's session are Tesla, Cisco, DowDuPont, T-Mobile and Express Scripts.
The activist investor recently disrupted the planned deal between Xerox Corp. and Fujifilm Holdings.
Activist investor Carl Icahn has built a sizable stake in Cigna Corp. and plans to vote against the health insurer’s $54 billion purchase of Express Scripts Holding Co., the latest sign of trouble for the planned tie-up. Mr. Icahn, whose stake amounts to less than 5% of Cigna’s shares outstanding, believes the company is paying too high a price for the pharmacy-benefit manager, which faces threats on a number of fronts, according to people familiar with the matter. Cigna in March agreed to pay what amounted to about $96.03 a share in cash and stock for Express Scripts.
On a per-share basis, the St. Louis-based company said it had net income of $1.55. Earnings, adjusted for non-recurring costs, came to $2.22 per share. The results beat Wall Street expectations. The average ...
- Reports 13% Consolidated GAAP Earnings Per Diluted Share Growth - Raises Core Adjusted EBITDA Guidance Range - Increases Client Retention Level - Projects 2% to 3% Core Adjusted Claims Growth for 2019 ...
Activist investor Carl Icahn has built a sizable stake in Cigna Corp. and plans to oppose the health insurer’s $54 billion takeover of pharmacy-benefits firm Express Scripts Holding Co., according to people familiar with the matter. Chief among Icahn’s concerns is that Amazon.com Inc.’s entrance into the prescription-drug industry could threaten Express Scripts’s business there over time, said the people. Express Scripts shares fell 6.3 percent to $74.44 at the close in New York, the biggest one-day drop since April 2017.